Breaking News Instant updates and real-time market news.

2022-05-18 08:22:25 PGR Progressive $111.16 / +1.45 (+1.32%) 08:22 05/18/22 05/18 08:22 05/18/22 08:22	Progressive reports April EPS (34c) vs. 54c last year Reports net premiums written $4.82B vs. $4.45B last year. Reports net premiums earned $4.61B vs. $4.13B last year. Reports combined ratio 95.5% vs. 96% last year.

2022-05-18 08:22:25

PGR

Progressive

$111.16 / +1.45 (+1.32%)

08:22

05/18/22

05/18

08:22

05/18/22

08:22

Progressive reports April EPS (34c) vs. 54c last year

Reports net premiums written $4.82B vs. $4.45B last year. Reports net premiums earned $4.61B vs. $4.13B last year. Reports combined ratio 95.5% vs. 96% last year.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	Ur-Energy signs agreement with U.S. nuclear utility » 17:35 08/08/22 08/08 17:35 08/08/22 17:35 URG Ur-Energy $1.18 / -0.01 (-0.84%) Ur-Energy announce that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Periodicals URG Ur-Energy $1.18 / -0.01 (-0.84%) 11/02/21 Alliance Global Partners Ur-Energy price target raised to $2.50 from $2.20 at Alliance Global Partners URG Ur-Energy $1.18 / -0.01 (-0.84%) 04/18/22 Energy Department set to announce $6B nuclear plant lifeline, Bloomberg says
Earnings	Mesa Air reports Q3 EPS (28c), consensus (22c) » 17:34 08/08/22 08/08 17:34 08/08/22 17:34 MESA Mesa Air $2.66 / +0.135 (+5.35%) Reports Q3 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events MESA Mesa Air $2.66 / +0.135 (+5.35%) 06/08/22 Mesa Air announces enhanced United Aviate partnership 04/22/22 Mesa Air appoints Amy Krallman as VP, human resources 03/01/22 Mesa Air appoints Christian Daoud as VP, maintenance and technical operations MESA Mesa Air $2.66 / +0.135 (+5.35%) 05/11/22 Deutsche Bank Mesa Air price target lowered to $3 from $5.50 at Deutsche Bank 02/04/22 Raymond James Mesa Air downgraded to Market Perform from Outperform at Raymond James 02/04/22 Raymond James Mesa Air downgraded to Market Perform from Outperform at Raymond James 01/07/22 BofA Mesa Air downgraded to Neutral from Buy at BofA MESA Mesa Air $2.66 / +0.135 (+5.35%) 05/09/22 Mesa Air reports Q2 EPS ( 29c), consensus (31c) 02/09/22 Mesa Air reports Q EPS (26c), consensus (12c) 16:30 Today Mesa Air - MESA
Hot Stocks	National Healthcare announces $25M stock repurchase authorization » 17:31 08/08/22 08/08 17:31 08/08/22 17:31 NHC National Healthcare $69.31 / +1.14 (+1.67%) National HealthCare… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings NHC National Healthcare $69.31 / +1.14 (+1.67%) 05/05/22 National Healthcare raises quarterly dividend by 3.6% to 57c per share NHC National Healthcare $69.31 / +1.14 (+1.67%) 02/18/22 National Healthcare reports Q4 adjusted EPS $1.02 vs. 90c last year
Hot Stocks	CorMedix receives CRL from FDA saying that DefenCath NDA cannot be approved » 17:31 08/08/22 08/08 17:31 08/08/22 17:31 CRMD CorMedix $7.50 / +0.39 (+5.49%) CorMedix announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings On The Fly Events CRMD CorMedix $7.50 / +0.39 (+5.49%) 05/12/22 CorMedix believes it has sufficient resources to fund through 1H of 2023 05/12/22 CorMedix announces leadership updates, operational changes 04/07/22 CorMedix announces SAB to support commercialization, pipeline development 03/28/22 CorMedix announces FDA acceptance of resubmission of NDA for DefenCath CRMD CorMedix $7.50 / +0.39 (+5.49%) 05/12/22 CorMedix reports Q1 EPS (18c), consensus (22c) 03/29/22 CorMedix reports Q4 EPS (20c), consensus (23c) CRMD CorMedix $7.50 / +0.39 (+5.49%) 03/29/22 Fly Intel: After-Hours Movers 08/11/22 CorMedix - CRMD
Syndicate	Cyteir Therapeutics files $300M mixed securities shelf 17:30 08/08/22 08/08 17:30 08/08/22 17:30 CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) ShowHide Related Items >><< Company News Street Research Earnings Events CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) 16:08 Today Cyteir Therapeutics expects cash to fund operations into second half of 2024 06/05/22 Cyteir Therapeutics presents CYT-0851 Phase 1 dose escalation results 04/25/22 Cyteir Therapeutics appoints Adam Veness as general counsel CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) 03/17/22 Wedbush Cyteir Therapeutics price target lowered to $30 from $40 at Wedbush 02/07/22 Northland Cyteir Therapeutics initiated with an Outperform at Northland CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) 16:08 Today Cyteir Therapeutics reports Q2 EPS (34c), consensus (44c) 05/05/22 Cyteir Therapeutics reports Q1 EPS (40c), consensus (39c) 03/16/22 Cyteir Therapeutics reports Q4 EPS (34c), consensus (39c) 00:00 Today Biotechnology Conference 08/09/22 Wedbush PacGrow Healthcare Virtual Conference
Syndicate	Biolase files to sell 1.41M shares of common stock for holders 17:30 08/08/22 08/08 17:30 08/08/22 17:30 BIOL Biolase $5.40 / +0.12 (+2.27%) ShowHide Related Items >><< Company News Street Research Earnings Events BIOL Biolase $5.40 / +0.12 (+2.27%) 07/25/22 Biolase receives five new United States patents, seven new foreign patents 07/13/22 Biolase announces pilot program with Einstein Healthcare Network's residency 07/07/22 Biolase promotes Jennifer Bright to CFO, Steven Sandor to COO 07/05/22 Biolase announces partnership with TeamSmile BIOL Biolase $5.40 / +0.12 (+2.27%) 05/20/22 Lake Street Biolase initiated with a Buy at Lake Street 08/19/21 Ascendiant Biolase price target raised to $3 from $2 at Ascendiant BIOL Biolase $5.40 / +0.12 (+2.27%) 05/12/22 Biolase sees Q2 revenue above $10.5M, consensus $10.2M 05/12/22 Biolase reports Q1 EPS (77c), consensus (68c) 08/11/22 Biolase - BIOL
Syndicate	CinCor Pharma files to sell 6M shares of common stock, pre-funded warrants » 17:29 08/08/22 08/08 17:29 08/08/22 17:29 CINC CinCor Pharma $34.96 / +11.46 (+48.77%) Goldman Sachs & Co.,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 07:24 Today CinCor Pharma announces data for Phase 2 BrigHtn trial evaluating baxdrostat 07:21 Today CinCor Pharma announces upcoming milestones 07/26/22 CinCor Pharma announces last patient randomized in Phase 2 HALO trial 06/01/22 CinCor Pharma doses first patient in Phase 2 figHTN-CKD trial CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 14:35 Today Oppenheimer CinCor Pharma price target raised to $60 from $35 at Oppenheimer 07/21/22 Oppenheimer CinCor Pharma price target raised to $35 from $30 at Oppenheimer 02/01/22 Oppenheimer CinCor Pharma initiated with an Outperform at Oppenheimer 02/01/22 Evercore ISI CinCor Pharma initiated with an Outperform at Evercore ISI CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 07:20 Today CinCor Pharma reports Q2 EPS (56c), consensus (50c) 05/10/22 CinCor Pharma reports Q1 EPS (50c), consensus (50c) 03/22/22 CinCor Pharma reports Q4 EPS ($15.71) vs. ($4.65) last year 07 Jan CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 16:46 Today What You Missed On Wall Street On Monday 12:12 Today What You Missed On Wall Street This Morning 03/26/22 Opening Day: AN2 Therapeutics rises in public debut after upsized IPO 08:30 Today CinCor Pharma - CINC CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 07/13/22 Two new option listings on July 13th
Earnings	Primoris reports Q2 adjusted EPS 48c, two estimates 59c » 17:29 08/08/22 08/08 17:29 08/08/22 17:29 PRIM Primoris $22.52 / +0.095 (+0.42%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PRIM Primoris $22.52 / +0.095 (+0.42%) 07/05/22 Primoris awarded contract at over $170M 06/27/22 Primoris enter agreement to acquire PLH in all-cash transaction valued at $470M 06/23/22 Primoris awarded $260M solar project 05/06/22 Primoris awarded $130M solar project PRIM Primoris $22.52 / +0.095 (+0.42%) 11/10/21 Goldman Sachs Goldman downgrades Primoris to Sell on 'bottom quintile' growth 11/10/21 Goldman Sachs Primoris downgraded to Sell from Neutral at Goldman Sachs PRIM Primoris $22.52 / +0.095 (+0.42%) 05/09/22 Primoris raises FY22 adjusted EPS view to $2.49-$2.69 from $2.39-$2.59 05/09/22 Primoris reports Q1 adjusted EPS 1c, consensus 9c 02/28/22 Primoris sees FY22 EPS $2.39-$2.59, consensus $2.50 02/28/22 Primoris reports Q4 EPS 63c, consensus 56c 08/09/22 Primoris - PRIM
Syndicate	Merchants Bancorp files $500M mixed securities shelf 17:27 08/08/22 08/08 17:27 08/08/22 17:27 MBIN Merchants Bancorp $27.72 / +0.445 (+1.63%) ShowHide Related Items >><< Company News Earnings MBIN Merchants Bancorp $27.72 / +0.445 (+1.63%) 02/17/22 Merchants Bancorp raises quarterly dividend 17% to 7c from 6c per share MBIN Merchants Bancorp $27.72 / +0.445 (+1.63%) 04/28/22 Merchants Bancorp reports Q1 EPS $1.02, consensus $1.00
Earnings	Freshpet backs FY22 revenue view of at least $575M, consensus $582.72M » 17:27 08/08/22 08/08 17:27 08/08/22 17:27 FRPT Freshpet $56.39 / +1.895 (+3.48%) Sees FY22 adjusted EBITDA… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events FRPT Freshpet $56.39 / +1.895 (+3.48%) 06/22/22 Freshpet recalls select product due to potential Salmonella contamination FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Atlantic Equities Atlantic Equities sees more volatility for Freshpet, downgrades shares 05/20/22 Atlantic Equities Freshpet downgraded to Neutral from Overweight at Atlantic Equities 05/03/22 Cowen Freshpet price target lowered to $163 from $181 at Cowen 05/03/22 Oppenheimer Freshpet price target lowered to $110 from $120 at Oppenheimer FRPT Freshpet $56.39 / +1.895 (+3.48%) 17:25 Today Freshpet reports Q2 EPS (45c), consensus (14c) 05/02/22 Freshpet backs FY22 revenue view at least $575M, consensus $576.99M 05/02/22 Freshpet reports Q1 EPS (40c), consensus (39c) 02/28/22 Freshpet sees FY22 revenue $575M, consensus $562.4M 04 May FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Proven algorithm says sell these stocks now 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/13/22 Short Report: Upstart shorts take profits as stock craters on guidance cut 05/13/22 Proven algorithm says sell these stocks now 16:30 Today Freshpet - FRPT 08/11/22 Freshpet

Syndicate	Rallybio files $300M mixed securities shelf 17:25 08/08/22 08/08 17:25 08/08/22 17:25 RLYB Rallybio $10.61 / -0.54 (-4.84%) ShowHide Related Items >><< Company News Street Research Earnings RLYB Rallybio $10.61 / -0.54 (-4.84%) 06/02/22 Rallybio announces Jeffrey Fryer to retire from CFO position 05/25/22 Rallybio director sold $1.3M in common stock 05/10/22 Rallybio announces in-licensing of Sanofi's KY1066 RLYB Rallybio $10.61 / -0.54 (-4.84%) 02/22/22 JMP Securities Rallybio initiated with an Outperform at JMP Securities 08/23/21 Evercore ISI Rallybio initiated with an Outperform at Evercore ISI 08/23/21 Cowen Rallybio initiated with an Outperform at Cowen 08/23/21 Jefferies Rallybio initiated with a Buy at Jefferies RLYB Rallybio $10.61 / -0.54 (-4.84%) 05/10/22 Rallybio reports Q1 EPS (48c), consensus (45c) 03/15/22 Rallybio reports Q4 EPS (42c), consensus (39c)
Earnings	Freshpet reports Q2 EPS (45c), consensus (14c) » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 FRPT Freshpet $56.39 / +1.895 (+3.48%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events FRPT Freshpet $56.39 / +1.895 (+3.48%) 06/22/22 Freshpet recalls select product due to potential Salmonella contamination FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Atlantic Equities Atlantic Equities sees more volatility for Freshpet, downgrades shares 05/20/22 Atlantic Equities Freshpet downgraded to Neutral from Overweight at Atlantic Equities 05/03/22 Cowen Freshpet price target lowered to $163 from $181 at Cowen 05/03/22 Oppenheimer Freshpet price target lowered to $110 from $120 at Oppenheimer FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/02/22 Freshpet backs FY22 revenue view at least $575M, consensus $576.99M 05/02/22 Freshpet reports Q1 EPS (40c), consensus (39c) 02/28/22 Freshpet sees FY22 revenue $575M, consensus $562.4M 02/28/22 Freshpet reports Q4 EPS (21c), consensus (16c) 04 May FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Proven algorithm says sell these stocks now 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/13/22 Short Report: Upstart shorts take profits as stock craters on guidance cut 05/13/22 Proven algorithm says sell these stocks now 16:30 Today Freshpet - FRPT 08/11/22 Freshpet
Conference/Events	CTI BioPharma management to meet virtually with BTIG » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) In conjunction with the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 06/10/22 CTI BioPharma presents data from pacritinib program at EHA 05/26/22 CTI BioPharma to present pivotal data on pacritinib program 04/14/22 CTI BioPharma's Vonjo included in NCCN Myeloproliferative Neoplasm guidelines 02/28/22 CTI BioPharma announces FDA accelerated approval of VONJO CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 11:28 Today Stifel Global Blood Therapeutics downgraded to Hold from Buy at Stifel 07/07/22 Cowen Cowen starts CTI BioPharma at Outperform on 'high growth opportunity' 07/07/22 Cowen CTI BioPharma initiated with an Outperform at Cowen 04/14/22 Stifel Stifel reiterates Buy on CTI BioPharma following new treatment guidelines CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 16:30 Today CTI BioPharma reports Q2 EPS (21c), consensus (20c) 05/12/22 CTI BioPharma reports Q1 EPS (23c), consensus (41c) 03/31/22 CTI BioPharma reports Q4 EPS (38c), consensus (28c) CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 06/27/22 Fly Insider: American Woodmark, Coursera among week's notable insider trades 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 04/01/22 What You Missed On Wall Street On Friday 00:00 Today Biotechnology Conference 08/15/22 2022 Biotech Summer Summit 08/09/22 CTI BioPharma - CTIC CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 05/12/22 CTI BioPharma options imply 10.5% move in share price post-earnings 04/18/22 Unusually active option classes on open April 18th 03/31/22 CTI BioPharma options imply 5.3% move in share price post-earnings 03/24/22 CTI BioPharma options imply 7.9% move in share price post-earnings
Conference/Events	Legend Biotech management to meet with BTIG » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 LEGN Legend Biotech $49.50 / -0.385 (-0.77%) BTIG Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 06/05/22 Legend Biotech presents results from CARTITUDE clinical development program 06/03/22 Legend Biotech announces FDA clearance of LB1908 IND application 05/26/22 Legend Biotech granted conditional marketing authorization for Carvykti by EC 05/09/22 Legend Biotech names Lori Macomber as CFO, effective immediately LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 06/16/22 BMO Capital Legend Biotech initiated with an Outperform at BMO Capital 05/31/22 Morgan Stanley Legend Biotech named Catalyst Driven Idea by Morgan Stanley 03/15/22 Barclays Legend Biotech initiated with an Overweight at Barclays LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 06/01/22 Legend Biotech reports Q1 EPS (13c), consensus (46c) 03/18/22 Legend Biotech reports Q4 EPS (30c), consensus (41c) 27 Jul 16 Dec LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 07/25/22 Fly Intel: After-Hours Movers 07/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 18:30 Today Legend Biotech
Conference/Events	Liquidia Technologies management to meet with BTIG » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) In conjunction with the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 08/01/22 Liquidia announces publication of long-term clinical data from INSPIRE study 07/25/22 Liquidia reports inducement grant under Nasdaq listing rule 07/19/22 Liquidia Technologies receives favorable ruling in IPR against UTC patent 07/19/22 USPTO says Liquidia established United Therapeutics' '793 patent 'unpatentable' LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 07/22/22 Ladenburg Ladenburg starts Liquidia Technologies at Buy with $15 price target 07/22/22 Ladenburg Liquidia Technologies initiated with a Buy at Ladenburg 07/20/22 BTIG Liquidia Technologies price target raised to $17 from $14 at BTIG 05/31/22 BTIG Liquidia Technologies initiated with a Buy at BTIG LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 05/12/22 Liquidia Technologies reports Q1 EPS (30c) vs. (21c) last year 15 Apr LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 07/22/22 What You Missed On Wall Street On Friday 07/22/22 What You Missed On Wall Street This Morning 07/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/13/22 What You Missed On Wall Street On Wednesday 08/11/22 Liquidia Technologies - LQDA 18:00 Today Liquidia Technologies
Conference/Events	Andersons management to meet with Stephens » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 ANDE Andersons $37.90 / -0.05 (-0.13%) Stephens holds a group… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ANDE Andersons $37.90 / -0.05 (-0.13%) 05/03/22 Andersons signs agreement to sell its railcar repair business ANDE Andersons $37.90 / -0.05 (-0.13%) 05/05/22 BMO Capital Andersons price target lowered to $45 from $50 at BMO Capital 03/25/22 Lake Street Andersons price target raised to $60 from $50 at Lake Street 02/17/22 Lake Street Andersons price target raised to $50 from $45 at Lake Street 11/29/21 Lake Street Andersons price target raised to $45 from $42 at Lake Street ANDE Andersons $37.90 / -0.05 (-0.13%) 08/02/22 Andersons reports Q2 adjusted EPS $2.39, consensus 98c 05/03/22 Andersons reports Q1 adjusted EPS 18c vs. 35c a year ago 02/15/22 Andersons reports Q4 adjusted EPS $1.14, consensus 66c 09/14/22 6th Annual Best Ideas Growth Conference: Big 6 18:00 Today Andersons
Syndicate	Cybin announces at-the-market equity program for up to $35M » 17:23 08/08/22 08/08 17:23 08/08/22 17:23 CYBN Cybin / + Cybin "announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CYBN Cybin / + 07/12/22 Cybin begins trial enrollment for CYB003 study for MDD treatment 06/27/22 Cybin announces additional Adelia milestone achievement 06/27/22 Cybin receives FDA IND clearance for Phase 1/2a trial evaluating CYB003 06/09/22 Cybin gets IRB approval for Phase 1/2a clinical trial of CYB003 in MDD CYBN Cybin / + 06/23/22 Canaccord Cybin undervalued relative to market size opportunity, says Canaccord 06/10/22 Canaccord Cybin shares remain significantly undervalued, says Canaccord 04/13/22 H.C. Wainwright H.C. Wainwright says Cybin preclinical data show continued innovation leadership 11/23/21 Stifel Cybin price target lowered to C$8.25 from C$10 at Stifel CYBN Cybin / + 17:10 Today Cybin reports Q1 cash, cash equivalents C$42.5M 00:00 Today 42nd Annual Global I Growth Conference
Hot Stocks	Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056 » 17:22 08/08/22 08/08 17:22 08/08/22 17:22 MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) , GSK GSK plc $40.31 / -0.27 (-0.67%) Mersana Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 16:35 Today Mersana Therapeutics trading resumes 16:00 Today Mersana Therapeutics trading halted, news pending 05/23/22 Mersana Therapeutics director Hack buys 216K shares of stock 05/19/22 Mersana announces FDA grant of orphan drug designation to XMT-2056 GSK GSK plc $40.31 / -0.27 (-0.67%) 10:43 Today GSK, IQVIA launch Vaccine Track platform 07/29/22 ViiV Healthcare presents five-year data at AIDS 2022 on fostemsavir 07/28/22 ViiV Healthcare announces data from unblinded phase of HPTN 084 study 07/28/22 GSK plc signs framework contract with EC for supply of Adjupanrix flu vaccine MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 05/10/22 Baird Mersana Therapeutics price target lowered to $18 from $23 at Baird 05/09/22 H.C. Wainwright Mersana price target lowered to $19 from $24 at H.C. Wainwright 11/10/21 Baird Mersana Therapeutics price target lowered to $23 from $30 at Baird 10/14/21 BTIG Mersana Therapeutics assumed with a Buy at BTIG GSK GSK plc $40.31 / -0.27 (-0.67%) 14:58 Today UBS GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS 08/05/22 Morgan Stanley GSK plc resumed with an Equal Weight at Morgan Stanley 07/21/22 Citi GSK plc resumed with a Neutral at Citi 07/20/22 UBS GSK plc price target lowered to 1,850 GBp from 1,876 GBp at UBS MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 16:24 Today Mersana Therapeutics reports Q2 EPS (55c), consensus (52c) 05/09/22 Mersana Therapeutics reports Q1 EPS (59c), consensus (32c) 02/28/22 Mersana Therapeutics reports Q4 EPS (68c), consensus (67c) GSK GSK plc $40.31 / -0.27 (-0.67%) 07/27/22 GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year 04/27/22 GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER 04/27/22 GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year 04/13/22 GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B GSK GSK GSK plc $40.31 / -0.27 (-0.67%) 07/18/22 GSK CEO says split will help deal with 'perennial underperformance,' FT reports 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says 06/06/22 GSK rectal cancer trial yields remission in all 18 patients, NY Times reports MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 04/14/22 What You Missed On Wall Street This Morning 02/09/22 Wall Street in Fives - Must Read Lists for Wednesday 02/09/22 Wall Street in Fives - Must Read Lists at Midday GSK GSK plc $40.31 / -0.27 (-0.67%) 08/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/18/22 What You Missed On Wall Street This Morning 07/18/22 Fly Intel: Pre-market Movers 06/24/22 What You Missed On Wall Street On Friday 06/08/22 Global Healthcare Conference 08/09/22 Wedbush PacGrow Healthcare Virtual Conference 09/10/22 ESMO Congress 2022 16:30 Today Mersana Therapeutics - MRSN GSK GSK GSK plc $40.31 / -0.27 (-0.67%) 07/29/22 GSK plc (ADR) call volume above normal and directionally bullish 07/22/22 Two new option listings and one option delisting on July 22nd 07/20/22 One new option listing and two option delistings on July 20th 07/08/22 GlaxoSmithKline call volume above normal and directionally bullish
Syndicate	Canoo files automatic mixed securities shelf 17:22 08/08/22 08/08 17:22 08/08/22 17:22 GOEV Canoo $3.95 / +0.26 (+7.05%) ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GOEV Canoo $3.95 / +0.26 (+7.05%) 16:52 Today Canoo sees second half of FY22 operating expenses $200M-$245M 07/14/22 Canoo's multi-purpose platform selected by Army for analysis & demostration 07/13/22 Canoo drops 5% after disclosing Walmart pact prevents sales to Amazon 07/13/22 Canoo says Walmart agreement prevents sales to Amazon GOEV Canoo $3.95 / +0.26 (+7.05%) 07/14/22 R.F. Lafferty Canoo price target lowered to $17 from $20 at R.F. Lafferty 07/13/22 H.C. Wainwright Canoo price target lowered to $10 from $15 at H.C. Wainwright 12/16/21 R.F. Lafferty Canoo price target raised to $21 from $19 at R.F. Lafferty 12/16/21 Roth Capital Roth Capital upgrades Canoo to Buy, raises price target to $14 GOEV Canoo $3.95 / +0.26 (+7.05%) 16:51 Today Canoo reports Q2 EPS (68c), consensus (53c) 05/10/22 Canoo reports Q1 EPS (54c), consensus (50c) 02/28/22 Canoo reports Q4 EPS (60c), consensus (51c) GOEV Canoo $3.95 / +0.26 (+7.05%) 02/11/22 Canoo has lost founders, key engineers post-SPAC, Business Insider reports GOEV Canoo $3.95 / +0.26 (+7.05%) 07/25/22 Fly Insider: CrossFirst Bankshares, Canoo among week's notable insider trades 07/23/22 Short Report: Revlon shorts recede, stock retreats as buyout news fades 07/18/22 What You Missed This Week in EVs and Clean Energy 07/16/22 Short Report: Canoo shorts going along for the ride 17:00 Today Canoo - GOEV GOEV Canoo $3.95 / +0.26 (+7.05%) 13:19 Today Canoo options imply 15.3% move in share price post-earnings 07/27/22 Largest borrow rate increases among liquid names 07/20/22 Largest borrow rate increases among liquid names 07/14/22 Unusually active option classes on open July 14th
Earnings	Aterian reports Q2 EPS (26), consensus (12c) » 17:22 08/08/22 08/08 17:22 08/08/22 17:22 ATER Aterian $2.97 / +0.225 (+8.20%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ATER Aterian $2.97 / +0.225 (+8.20%) 04/18/22 Aterian appoints Anton von Rueden as COO 04/01/22 Aterian appoints Cynthia Williams to board of directorsHasbro 03/02/22 Aterian announces pricing of $27.5M private placement ATER Aterian $2.97 / +0.225 (+8.20%) 03/11/22 Alliance Global Partners Aterian price target lowered to $4.50 from $9 at Alliance Global Partners 03/09/22 BTIG Aterian price target lowered to $5 from $9 at BTIG 03/09/22 DA Davidson Aterian price target lowered to $7 from $14 at DA Davidson 02/11/22 Alliance Global Partners Aterian price target lowered to $9 from $13 at Alliance Global Partners ATER Aterian $2.97 / +0.225 (+8.20%) 05/09/22 Aterian reports Q1 EPS (78c), consensus (25c) 03/08/22 Aterian reports Q4 EPS (11c), consensus (12c) ATER Aterian $2.97 / +0.225 (+8.20%) 05/10/22 Fly Intel: Pre-market Movers 05/09/22 Fly Intel: After-Hours Movers 04/18/22 What You Missed On Wall Street On Monday 04/18/22 What You Missed On Wall Street This Morning 17:00 Today Aterian - ATER ATER Aterian $2.97 / +0.225 (+8.20%) 15:04 Today Aterian options imply 16.3% move in share price post-earnings 06/09/22 Largest borrow rate increases among liquid names 05/25/22 Largest borrow rate increases among liquid names 05/20/22 Largest borrow rate increases among liquid names

Earnings	Granite Point Mortgage reports Q2 EPS 22c, consensus 22c » 17:21 08/08/22 08/08 17:21 08/08/22 17:21 GPMT Granite Point Mortgage $10.43 / +0.1 (+0.97%) Jack Taylor, President,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Events 08/09/22 Granite Point Mortgage - GPMT
Earnings	Inhibrx reports Q2 EPS (97c), consensus (78c) » 17:21 08/08/22 08/08 17:21 08/08/22 17:21 INBX Inhibrx $24.67 / +1.56 (+6.75%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings INBX Inhibrx $24.67 / +1.56 (+6.75%) 06/30/22 Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan 05/16/22 Inhibrx's INBRX-101 shows favorable safety profile in Phase 1 AATD trial 04/25/22 Inhibrx announces formation of Scientific Advisory Board for INBRX-101 03/03/22 Inhibrx's INBRX-101 granted FDA Orphan-Drug Designation INBX Inhibrx $24.67 / +1.56 (+6.75%) 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko 11/10/21 Credit Suisse Inhibrx price target raised to $53 from $44 at Credit Suisse 11/02/21 JMP Securities Inhibrx price target raised to $53 from $46 at JMP Securities INBX Inhibrx $24.67 / +1.56 (+6.75%) 05/09/22 Inhibrx reports Q1 EPS (80c), consensus (60c) 02/28/22 Inhibrx reports Q4 EPS (55c), consensus (57c)
Earnings	Prothena reports Q2 EPS (88c) vs. 58c last year » 17:19 08/08/22 08/08 17:19 08/08/22 17:19 PRTA Prothena $33.07 / +0.01 (+0.03%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PRTA Prothena $33.07 / +0.01 (+0.03%) 05/05/22 Prothena backs FY22 net cash used in operating /investing 120M-$132M 04/26/22 Prothena receives Fast Track designation for PRX012 03/28/22 Prothena announces FDA clearance of IND for PRX012 03/16/22 Prothena announces new preclinical data from dual Ass/tau vaccine for AD PRTA Prothena $33.07 / +0.01 (+0.03%) 05/25/22 JMP Securities Prothena price target lowered to $50 from $77 at JMP Securities 02/18/22 Citi Prothena price target lowered to $73 from $87 at Citi 11/19/21 JMP Securities Prothena initiated with an Outperform at JMP Securities 09/30/21 RBC Capital Prothena price target raised to $82 from $59 at RBC Capital PRTA Prothena $33.07 / +0.01 (+0.03%) 05/05/22 Prothena reports Q1 EPS (78c), consensus (68c) 02/17/22 Prothena reports Q4 EPS (71c), consensus (58c)
Earnings	Clover Health reports Q2 revenue $846.7M, consensus $814.62M » 17:16 08/08/22 08/08 17:16 08/08/22 17:16 CLOV Clover Health $3.40 / +0.14 (+4.30%) Reports total lives under… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options CLOV Clover Health $3.40 / +0.14 (+4.30%) 07/14/22 Clover Health announces planned medicare edvantage expansion for 2023 06/24/22 Clover Health is set to join the Russell 3000 Index 05/25/22 Clover Health appoints Scott Leffler as CFO 03/14/22 Clover Health appoints Joseph Martin as general counsel CLOV Clover Health $3.40 / +0.14 (+4.30%) 02/24/22 Canaccord Clover Health price target raised to $7 from $6 at Canaccord 02/17/22 Citi Citi opens 'negative catalyst watches' in health care services 02/02/22 Cowen Clover Health upgraded to Market Perform from Underperform at Cowen 01/19/22 SVB Leerink Clover Health initiated with a Market Perform at SVB Leerink CLOV Clover Health $3.40 / +0.14 (+4.30%) 05/09/22 Clover Health reaffirms FY22 revenue view $3.0B-$3.4B, consensus $3.24B 05/09/22 Clover Health reports Q1 revenue $874.4M, consensus $787.41M 02/23/22 Clover Health sees FY22 revenue $3.0B-$3.4B, consensus $2.62B 02/23/22 Clover Health reports Q4 adjusted EBITDA ($68.5M) vs ($41.5M) last year 18 Nov CLOV Clover Health $3.40 / +0.14 (+4.30%) 05/10/22 Fly Intel: Pre-market Movers 05/09/22 Fly Intel: After-Hours Movers 02/24/22 What You Missed On Wall Street On Thursday 02/24/22 What You Missed On Wall Street This Morning 17:00 Today Clover Health - CLOV CLOV Clover Health $3.40 / +0.14 (+4.30%) 13:34 Today Clover Health options imply 12.4% move in share price post-earnings 07/18/22 Unusually active option classes on open July 18th 06/27/22 Unusually active option classes on open June 27th 06/21/22 Unusually active option classes on open June 21st
Periodicals	'Horizon Forbidden West' retakes top sales spot in U.K., Gamesindustry.biz says » 17:14 08/08/22 08/08 17:14 08/08/22 17:14 SONY Sony $84.84 / -1.46 (-1.69%) , NTDOY Nintendo $53.24 / -0.82 (-1.52%) , WBD Warner Bros. Discovery $14.01 / -0.58 (-3.98%) , MSFT Microsoft $280.35 / -2.78 (-0.98%) , EA Electronic Arts $131.09 / -1.48 (-1.12%) PlayStation (SONY)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SONY NTDOY WBD MSFT EA SONY Sony $84.84 / -1.46 (-1.69%) 17:01 Today Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023 08/07/22 Fly Intel: Top five weekend stock stories 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD 07/28/22 Backbone introduces Backbone One PlayStation Edition for iPhone users NTDOY Nintendo $53.24 / -0.82 (-1.52%) 17:01 Today Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023 08/03/22 Nintendo sold 3.43M Switch consoles in Q1 vs. 4.45M last year 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD 07/15/22 Bandai Namco's 'Elden Ring' best selling game in U.S. in June, says NPD WBD Warner Bros. Discovery $14.01 / -0.58 (-3.98%) 08/04/22 Warner Bros. Discovery backs long-term leverage target of 2.5-3.0 08/04/22 Warner Bros. Discovery sees FY23 adjusted EBITDA of 'at least $12B' 08/04/22 AT&T, Warner Bros. Discovery announces distribution pact for HBO Max 08/04/22 Warner Bros. Discovery launches dedicated CNN Originals hub on discovery+ MSFT Microsoft $280.35 / -2.78 (-0.98%) 17:01 Today Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023 08/04/22 Atlassian names Microsoft's Joe Binz as new CFO 08/04/22 Microsoft tests Game Pass family plan in Colombia, Ireland 08/03/22 Microsoft testing PC Game Pass widget on Windows 11 EA Electronic Arts $131.09 / -1.48 (-1.12%) 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD 08/02/22 Electronic Arts, LaLiga enter multi-year partnership 07/25/22 Electronic Arts, Juventus Football Club enter multiyear partnership 07/19/22 Electronic Arts CTO Kenneth Moss to leave company SONY NTDOY WBD MSFT EA SONY Sony $84.84 / -1.46 (-1.69%) 07/08/22 Macquarie Sony upgraded to Outperform, added to 'Marquee Buy' list at Macquarie 07/05/22 Citi Sony downgraded to Neutral from Buy at Citi 05/18/22 Oppenheimer Sony price target lowered to $125 from $150 at Oppenheimer 04/13/22 CLSA Sony downgraded to Outperform from Buy at CLSA NTDOY Nintendo $53.24 / -0.82 (-1.52%) 05/24/22 CLSA Nintendo price target lowered to 51,000 yen from 53,000 yen at CLSA 03/23/22 Macquarie Nintendo upgraded to Outperform from Neutral at Macquarie 02/16/22 Jefferies Nintendo upgraded to Buy from Hold at Jefferies 11/05/21 Macquarie Nintendo downgraded to Neutral from Outperform at Macquarie WBD Warner Bros. Discovery $14.01 / -0.58 (-3.98%) 09:00 Today Barrington Warner Bros. Discovery downgraded to Market Perform from Outperform at Barrington 08/05/22 Wells Fargo Warner Bros. Discovery downgraded to Equal Weight at Wells Fargo 08/05/22 Barclays Warner Bros. Discovery price target lowered to $17 from $19 at Barclays 08/04/22 Credit Suisse Warner Bros. Discovery price target lowered to $43 from $52 at Credit Suisse MSFT Microsoft $280.35 / -2.78 (-0.98%) 09:27 Today B. Riley B. Riley thinks Globalstar's mystery satellite capacity customer is Apple 08/04/22 MKM Partners 8x8 initiated with a Neutral at MKM Partners 08/04/22 Deutsche Bank Activision Blizzard price target lowered to $84 from $95 at Deutsche Bank 08/03/22 Craig-Hallum RingCentral price target lowered to $110 from $175 at Craig-Hallum EA Electronic Arts $131.09 / -1.48 (-1.12%) 08/04/22 Wells Fargo Electronic Arts price target raised to $155 from $145 at Wells Fargo 08/03/22 Morgan Stanley PayPal price target raised to $134 from $129 at Morgan Stanley 08/03/22 Credit Suisse Electronic Arts price target lowered to $154 from $159 at Credit Suisse 08/03/22 BofA Electronic Arts price target raised to $155 from $148 at BofA SONY NTDOY WBD MSFT EA SONY Sony $84.84 / -1.46 (-1.69%) 07/29/22 Sony raises FY22 consolidated sales view Y11.5T from Y11.4T 07/29/22 Sony reports Q1 revenue Y2.31T vs. Y2.26T last year 05/10/22 Sony sees FY22 consolidated sales Y11.4T vs. Y9.921B in FY21 05/10/22 Sony reports FY21 revenue Y9.921B vs. Y8.998B last year NTDOY Nintendo $53.24 / -0.82 (-1.52%) 08/03/22 Nintendo sees FY net sales Y1.6T, operating profit Y500B 08/03/22 Nintendo reports Q1 revenue Y307.46B vs. Y322.65B last year 05/10/22 Nintendo reports FY revenue Y1.70T vs. Y1.8T last year WBD Warner Bros. Discovery $14.01 / -0.58 (-3.98%) 08/04/22 Warner Bros. Discovery cuts FY22 adjusted EBITDA view to $9.0B-$9.5B 08/04/22 Warner Bros. Discovery reports Q2 EPS with items ($1.50), consensus (3c) 08/04/22 Notable companies reporting after market close 04/26/22 Warner Bros. Discovery reports Q1 diluted EPS 69c vs. 21c a year ago MSFT Microsoft $280.35 / -2.78 (-0.98%) 07/26/22 Microsoft sees FY23 revenue growth in double digits, consensus $225.98B 07/26/22 Microsoft reports Q4 EPS $2.23, consensus $2.30 07/26/22 Notable companies reporting after market close 06/02/22 Microsoft lowers Q4 EPS view to $2.24-$2.32 from $2.28-$2.35, consensus $2.33 EA Electronic Arts $131.09 / -1.48 (-1.12%) 08/02/22 Electronic Arts sees FY23 revenue $7.6B-$7.8B, consensus $7.99B 08/02/22 Electronic Arts reports Q1 EPS $1.11 vs. 71c last year 08/02/22 Notable companies reporting after market close 05/10/22 Electronic Arts sees Q1 EPS 76c-85c, consensus 83c SONY NTDOY WBD MSFT EA SONY Sony $84.84 / -1.46 (-1.69%) 08/01/22 Sony says Microsoft owning 'Call of Duty' could affect console choice, VGC says 07/26/22 'Star Wars: KOTOR' remake delayed indefinitely, Bloomberg reports 07/21/22 Europe game sales rose 13.5% year-over-year in 1H22, Gamesindustry.biz says 07/18/22 PlayStation acquires esports tech platform Repeat.gg, Gamesindustry.biz says NTDOY Nintendo $53.24 / -0.82 (-1.52%) 08/04/22 Nintendo not releasing new hardware this fiscal year, Nikkei reports 07/21/22 Europe game sales rose 13.5% year-over-year in 1H22, Gamesindustry.biz says 07/13/22 Europe game console sales grew 21.5% from May to June, Gamesindustry.biz says 07/06/22 Nintendo Switch sales rise 24% y/y in U.K. in June, Gamesindustry.biz says WBD Warner Bros. Discovery $14.01 / -0.58 (-3.98%) 08/05/22 Warner Bros. Discovery exploring free, ad-supported streaming, WSJ reports 08/04/22 Warner Bros. Discovery to combine HBO Max, Discovery+ next summer, Verge says 08/04/22 Warner Bros. Discovery to restructure HBO Max, Discovery+, TheWrap reports 08/03/22 Warner Bros. removes 6 exclusive HBO Max films from service, Indiewire says MSFT Microsoft $280.35 / -2.78 (-0.98%) 08/04/22 Microsoft provides Xbox Series S devs with more memory, Verge says 08/01/22 Sony says Microsoft owning 'Call of Duty' could affect console choice, VGC says 07/27/22 Microsoft seeks help to cut Amazon's cloud lead with U.S. government, WSJ says 07/26/22 'Star Wars: KOTOR' remake delayed indefinitely, Bloomberg reports EA Electronic Arts $131.09 / -1.48 (-1.12%) 07/25/22 EA making Black Panther video game, VentureBeat says 07/21/22 Europe game sales rose 13.5% year-over-year in 1H22, Gamesindustry.biz says 07/18/22 EA files patent for technique to generate content based on playstyle, VGC says 07/13/22 Europe game console sales grew 21.5% from May to June, Gamesindustry.biz says SONY NTDOY WBD MSFT EA SONY Sony $84.84 / -1.46 (-1.69%) 08/07/22 Box Office Battle: ‘Bullet Train’ wins weekend with $30.1M debut 08/02/22 What You Missed This Week in Video Games 07/31/22 Box Office Battle: ‘DC League of Super-Pets’ wins weekend with $23M debut 07/26/22 What You Missed This Week in Video Games NTDOY Nintendo $53.24 / -0.82 (-1.52%) 08/02/22 What You Missed This Week in Video Games 07/26/22 What You Missed This Week in Video Games 07/19/22 What You Missed This Week in Video Games 07/12/22 What You Missed This Week in Video Games WBD Warner Bros. Discovery $14.01 / -0.58 (-3.98%) 16:46 Today What You Missed On Wall Street On Monday 12:12 Today What You Missed On Wall Street This Morning 09:48 Today Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/07/22 Box Office Battle: ‘Bullet Train’ wins weekend with $30.1M debut MSFT Microsoft $280.35 / -2.78 (-0.98%) 08/02/22 What You Missed This Week in Video Games 07/27/22 What You Missed On Wall Street On Wednesday 07/27/22 What You Missed On Wall Street This Morning 07/27/22 Fly Intel: Pre-market Movers EA Electronic Arts $131.09 / -1.48 (-1.12%) 08/02/22 What You Missed This Week in Video Games 07/26/22 What You Missed This Week in Video Games 07/19/22 What You Missed This Week in Video Games 07/12/22 What You Missed This Week in Video Games 09/08/22 Consumer/Media/Entertainment Conference 11/01/22 Electronic Arts - EA 08/11/22 Electronic Arts Inc WBD MSFT EA WBD Warner Bros. Discovery $14.01 / -0.58 (-3.98%) 08/05/22 Notable open interest changes for August 5th 08/04/22 Notable open interest changes for August 4th 08/03/22 Warner Bros Discovery Inc call volume above normal and directionally bullish 07/25/22 Unusually active option classes on open July 25th MSFT Microsoft $280.35 / -2.78 (-0.98%) 07/28/22 Notable open interest changes for July 28th 07/26/22 Microsoft options imply 4.7% move in share price post-earnings 06/03/22 Unusually active option classes on open June 3rd 06/02/22 Unusually active option classes on open June 2nd EA Electronic Arts $131.09 / -1.48 (-1.12%) 05/24/22 Electronic Arts call volume above normal and directionally bullish 05/11/22 Early notable gainers among liquid option names on May 11th 02/22/22 Electronic Arts call volume above normal and directionally bullish

Events

Earnings calls, analyst events, roadshows and more

ANDE
Today at 18:00

Andersons Firm Sponsored Meetings

New York, NY
LQDA
Today at 18:00

Liquidia Technologies Firm Sponsored Meetings

New York, NY
LEGN
Today at 18:30

Legend Biotech Firm Sponsored Meetings

New York, NY
BBIO
Today at 18:30

BridgeBio Firm Sponsored Meetings

New York, NY
YALA
Today at 20:00

Yalla - YALA Conference Calls
Tomorrow at 00:00

E&P Meeting Circuit--Dingmann Conferences

Denver, CO
AVID ...
Tomorrow at 00:00

25th Annual Technology, Internet & Communications Virtual Conference Conferences

Virtual Conference
SYNA ...
Tomorrow at 00:00

23rd Annual Technology Leadership Forum Conferences

Vail, CO
Tomorrow at 00:00

Hot Wheels Bus Tour Conferences

New York/New Jersey
MTZ ...
Tomorrow at 00:00

8th Annual Communications Infrastructure Summit Conferences

Boulder, CO

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord $0.59 MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities $1.78 PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist $12.40-12.70
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies $241.19 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity $5.00 3M Shares PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler $28.44 8M Shares SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital $16.01 8.5M Shares
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Progressive reports April EPS (34c) vs. 54c last year

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access